Durvalumab (Medi4736) And Tremelimumab For Hepatocellular Carcinoma In Patients Listed For A Liver Transplant
Posted Date: Nov 14, 2023
- Investigator: William Chapman
- Type of Study: Drug
This is a Phase II multicenter clinical trial designed to evaluate the safety and efficacy of durvalumab and tremelimumab for the treatment of hepatocellular carcinoma (HCC) patients who have cirrhosis or portal hypertension and are listed for a liver transplant. Patients will receive treatment with immunotherapy (durvalumab and tremelimumab) for up to four months prior to undergoing a liver transplant. If you or a loved one is dealing with liver cancer (hepatocellular carcinoma or HCC) and is listed for a liver transplant, we have an opportunity that may interest you. Our team is conducting a Phase II multicenter clinical trial to explore a new treatment avenue that could significantly impact your journey toward recovery. This trial is specifically designed for HCC patients who also have cirrhosis or portal hypertension. We are investigating the safety and efficacy of two immunotherapy drugs, Durvalumab and Tremelimumab. These drugs have shown promise in advanced liver cancer cases, and our trial aims to understand their potential to improve outcomes for patients like you who are preparing for a liver transplant. As a participant, you would receive immunotherapy treatment with Durvalumab and Tremelimumab for up to four months before your scheduled liver transplant. This approach is based on the latest scientific insights and aims to harness your body’s immune system to fight the cancer more effectively. We understand that the journey through liver cancer treatment is challenging, and deciding to participate in a clinical trial is a significant step. Our team is committed to ensuring your safety and well-being throughout the trial. By joining us, you would be accessing potentially groundbreaking treatment and contributing to medical research that could benefit many others in similar situations. We invite you to consider this opportunity and would be happy to provide more detailed information and answer any questions you may have. Your participation could be a key step towards improving your health and the future of liver cancer treatment.
Criteria:
To Be Eligible For Our Phase Ii Clinical Trial For Hepatocellular Carcinoma (Hcc) Treatment, Participants Must Meet Specific Criteria. Firstly, They Should Have A Confirmed Diagnosis Of Hcc, Either Through A Biopsy Or By A Combination Of Cirrhosis And Imaging Criteria, Using Contrast-Enhanced Ct (Computed Tomography) Or Mri (Magnetic Resonance Imaging). Additionally, Participants Must Have Been Evaluated By An Institutional Liver Transplant Team And Officially Listed For A Transplant. Another Key Criterion Is The Presence Of At Least One Lesion That Qualifies As A Recist 1.1 Target Lesion (Tl) At Baseline And Has Not Been Previously Treated With Radiation. To Ensure The Most Current Assessment Of The Tumor, A Ct Scan Or Mri Must Be Performed Within 28 Days Prior To Randomization Into The Trial. Lastly, It's Crucial That Participants Have Not Received Any Prior Therapy For Hcc At Any Time. Meeting These Criteria Ensures That Patients Are Suitable For This Clinical Trial's Specific Interventions And Objectives. Be Age =18 Years At The Time Of Study Entry. Not Have Extrahepatic Disease Or Any Autoimmune Disease That Is Considered A Risk In The Setting Of Immunotherapy Per The Physician's Judgment.
Keywords:
Hepatocellular Carcinoma, Liver Cancer, Liver Transplant
For More Information:
Lauren Cartheuser
513-584-7698
carthelr@ucmail.uc.edu